source
- FDA rejects Capricor’s Duchenne cell therapy after trials show no benefitThe Food and Drug Administration announced that it is rejecting deramiocel, a cell therapy for Duchenne muscular dystrophy developed by Capricor Therapeutics. The treatment was aimed at teenage an…
- FDA leadership search continues as lung cancer drug faces rejection and China’s top drugmakers are rankedThe Readout LOUD podcast this week highlighted three main topics: the FDA’s ongoing search for a new commissioner, a setback for a closely watched lung cancer therapy, and a ranking of China’s bigg…